ATP-citrate lyase

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Cat.No.	Product Name	Information	Product Use Citations
S0277	BMS303141	BMS-303141 is a potent, cell-permeable inhibitor of ATP-citrate lyase (ACL) with IC50 of 0.13 μM. BMS-303141 shows inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells.	Phytomedicine, 2025, 140:156573 Blood Neoplasia, 2025, 2(2):100069 Cell Death Dis, 2023, 14(7):401
S8878	NDI-091143	NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay.	Redox Biol, 2025, 82:103606 JACC Basic Transl Sci, 2025, 10(7):101301 Adv Sci (Weinh), 2024, 11(46):e2401311
E1287	SB 204990	SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 potently limits SARS-CoV-2 replication in vivo.
S4864	2-Furoic acid	2-Furoic acid (2-Furancarboxylic acid, Pyromucic acid, 2-Carboxyfuran, α-furancarboxylic acid, α-furoic acid) is an organic compound most widely found in food products as a preservative and a flavoring agent.
E1768	MEDICA16	MEDICA16 is an inhibitor of ATP-citrate lyase and also acts as an agonist of G protein-coupled receptor 40 (GPR40). It functions to blunt the development of insulin resistance in the JCR:LA-cp rat as well as it is a potent triacylglycerol-lowering agent.
S7953	Bempedoic acid (ETC-1002)	Bempedoic acid (ETC-1002) is an orally available, once-daily LDL-C lowering small molecule designed to reduce elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. This compound is an activator of hepatic AMP-activated protein kinase (AMPK) and has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).	Cancer Cell, 2025, 43(4):776-796.e14 iScience, 2023, 26(12):108532 Oncol Rep, 2023, 49(2)32